Back

L-2-hydroxyglutarate dehydrogenase (L2HGDH) is a novel metabolic target protecting from cardiac hypertrophy and heart failure

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Rapid Fire 1 - Basic Science Cardiac Hypertrophy HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Anca Remes

Christian-Albrechts-University Kiel, Kiel (Germany)

11 More presentations in this session

Presentation thumbnail
Dual Regulation of SUMO2 and STAT1 by HectD3 Protects Heart from Hypertrophy and Inflammation
Doctor A. Rangrez (Kiel, DE)
Abstract
Presentation thumbnail
A translational mouse model of HFpEF
Mr A. Withaar (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Diastolic dysfunction and HFpEF characteristics are exacerbated with ageing in smoothelin-like 1 (SMTNL1)-deficient mice
Ms M. Murali (Calgary, CA)
Abstract Slides Video
Presentation thumbnail
Increased granulocyte neprilysin (CD10) expression is associated with better prognosis in patients with heart failure with reduced ejection fraction
Doctor H. Arfsten (Vienna, AT)
Abstract
Presentation thumbnail
Purified exosome product and extracellular vesicles: treatment for acute myocarditis, dilated cardiomyopathy and heart failure
Doctor K. Bruno (Jacksonville, US)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid Fire 1 - Basic Science

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019
You may be interested in
thumbnail
Webinar
Elevating cardiac expertise: practical approach to left ventricular hypertrophy phenotypes assessment
thumbnail
Congress Presentation
Multimodality imaging in hypertrophied hearts
thumbnail
Congress Presentation
Contemporary treatment of hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources